A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)
Latest Information Update: 11 Apr 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Capecitabine; Doxorubicin liposomal; Glucose; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-B49; MK-3475-B49/KEYNOTE-B49
- Sponsors Merck Sharp & Dohme Corp.
- 01 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 08 Feb 2023 Planned End Date changed from 21 Oct 2027 to 21 Jul 2028.
- 08 Feb 2023 Planned primary completion date changed from 21 Oct 2027 to 21 Jul 2028.